BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37212283)

  • 1. Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding.
    Adriaenssens A; Broichhagen J; de Bray A; Ast J; Hasib A; Jones B; Tomas A; Burgos NF; Woodward O; Lewis J; O'Flaherty E; El K; Cui C; Harada N; Inagaki N; Campbell J; Brierley D; Hodson DJ; Samms R; Gribble F; Reimann F
    JCI Insight; 2023 May; 8(10):. PubMed ID: 37212283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-dependent insulinotropic polypeptide receptor systems in the hypothalamus and the brainstem regulate feeding and weight through distinct pathways.
    Yada T
    J Diabetes Investig; 2024 Mar; 15(3):282-284. PubMed ID: 38140849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
    Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
    Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
    Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
    Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
    Zhang Q; Delessa CT; Augustin R; Bakhti M; Colldén G; Drucker DJ; Feuchtinger A; Caceres CG; Grandl G; Harger A; Herzig S; Hofmann S; Holleman CL; Jastroch M; Keipert S; Kleinert M; Knerr PJ; Kulaj K; Legutko B; Lickert H; Liu X; Luippold G; Lutter D; Malogajski E; Medina MT; Mowery SA; Blutke A; Perez-Tilve D; Salinno C; Sehrer L; DiMarchi RD; Tschöp MH; Stemmer K; Finan B; Wolfrum C; Müller TD
    Cell Metab; 2021 Apr; 33(4):833-844.e5. PubMed ID: 33571454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
    Adriaenssens AE; Biggs EK; Darwish T; Tadross J; Sukthankar T; Girish M; Polex-Wolf J; Lam BY; Zvetkova I; Pan W; Chiarugi D; Yeo GSH; Blouet C; Gribble FM; Reimann F
    Cell Metab; 2019 Nov; 30(5):987-996.e6. PubMed ID: 31447324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
    Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
    Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of energy metabolism through central GIPR signaling.
    Liskiewicz A; Müller TD
    Peptides; 2024 Jun; 176():171198. PubMed ID: 38527521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models.
    Borner T; Geisler CE; Fortin SM; Cosgrove R; Alsina-Fernandez J; Dogra M; Doebley S; Sanchez-Navarro MJ; Leon RM; Gaisinsky J; White A; Bamezai A; Ghidewon MY; Grill HJ; Crist RC; Reiner BC; Ai M; Samms RJ; De Jonghe BC; Hayes MR
    Diabetes; 2021 Nov; 70(11):2545-2553. PubMed ID: 34380697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Food-intake dysregulation in type 2 diabetic Goto-Kakizaki rats: hypothesized role of dysfunctional brainstem thyrotropin-releasing hormone and impaired vagal output.
    Zhao K; Ao Y; Harper RM; Go VL; Yang H
    Neuroscience; 2013 Sep; 247():43-54. PubMed ID: 23701881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders.
    Samms RJ; Sloop KW; Gribble FM; Reimann F; Adriaenssens AE
    Diabetes; 2021 Sep; 70(9):1938-1944. PubMed ID: 34176786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
    Regazzo D; Barbot M; Scaroni C; Albiger N; Occhi G
    Rev Endocr Metab Disord; 2020 Mar; 21(1):165-183. PubMed ID: 31933128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIP-GIPR promotes neurite outgrowth of cortical neurons in Akt dependent manner.
    Teng L; Guan T; Guo B; Ma C; Lin G; Wu R; Xu M; Liu M; Liu Y
    Biochem Biophys Res Commun; 2021 Jan; 534():121-127. PubMed ID: 33321289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
    Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth.
    Buhren BA; Gasis M; Thorens B; Müller HW; Bosse F
    J Neurosci Res; 2009 Jun; 87(8):1858-70. PubMed ID: 19170165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders.
    Verma MK; Goel R; Krishnadas N; Nemmani KVS
    Expert Opin Ther Targets; 2018 Jul; 22(7):615-628. PubMed ID: 29911915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system.
    Adriaenssens AE; Gribble FM; Reimann F
    Peptides; 2020 Mar; 125():170194. PubMed ID: 31697967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior.
    Samms RJ; Cosgrove R; Snider BM; Furber EC; Droz BA; Briere DA; Dunbar J; Dogra M; Alsina-Fernandez J; Borner T; De Jonghe BC; Hayes MR; Coskun T; Sloop KW; Emmerson PJ; Ai M
    Diabetes; 2022 Jul; 71(7):1410-1423. PubMed ID: 35499381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.